{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:03:27Z","timestamp":1791291807695,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81701733"],"award-info":[{"award-number":["81701733"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13139-024-00849-2","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T05:02:32Z","timestamp":1708750952000},"page":"279-290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Synthesis and Biologic Evaluation of an Iodine-Labeled Entecavir Derivative for Anti-hepatitis B Virus Activity"],"prefix":"10.1007","volume":"58","author":[{"given":"Mu hua","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang jun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"849_CR1","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.cgh.2023.04.015","volume":"21","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Wong G, Anstee QM, Henry L. The global burden of liver disease. Clin Gastroenterol Hepatol. 2023;21:1978\u201391.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"849_CR2","doi-asserted-by":"crossref","unstructured":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-85.","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"849_CR3","volume":"14","author":"SRR Butt","year":"2022","unstructured":"Butt SRR, Satnarine T, Ratna P, Sarker A, Ramesh AS, Munoz C, et al. A systematic review on current trends in the treatment of chronic hepatitis b to predict disease remission and relapse. Cureus. 2022;14: e32247.","journal-title":"Cureus."},{"key":"849_CR4","first-page":"204993612098595","volume":"8","author":"L Roade","year":"2021","unstructured":"Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis. 2021;8:2049936120985954.","journal-title":"Ther Adv Infect Dis."},{"key":"849_CR5","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1517\/13543784.12.4.683","volume":"12","author":"P Honkoop","year":"2003","unstructured":"Honkoop P, De Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs. 2003;12:683\u20138.","journal-title":"Expert Opin Investig Drugs."},{"key":"849_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","volume":"72","author":"M Cornberg","year":"2020","unstructured":"Cornberg M, Lok AS, Terrault NA, Zoulim F. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(\u2021). J Hepatol. 2020;72:539\u201357.","journal-title":"J Hepatol."},{"key":"849_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","volume":"66","author":"CL Lai","year":"2017","unstructured":"Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66:275\u201381.","journal-title":"J Hepatol."},{"key":"849_CR8","doi-asserted-by":"crossref","unstructured":"Malcolm J, Falzone N, Lee BQ, Vallis KA. Targeted radionuclide therapy: New advances for improvement of patient management and response. Cancers (Basel). 2019;11(2):268.","DOI":"10.3390\/cancers11020268"},{"key":"849_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.4149\/neo_2017_501","volume":"64","author":"M Widel","year":"2017","unstructured":"Widel M. Radionuclides in radiation-induced bystander effect; may it share in radionuclide therapy? Neoplasma. 2017;64:641\u201354.","journal-title":"Neoplasma."},{"key":"849_CR10","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1080\/00397919308011257","volume":"23","author":"PM Gannett","year":"1993","unstructured":"Gannett PM, Sura TP. An improved synthesis of 8-bromo-2\u2032-deoxyguanosine. Synth Commun. 1993;23:1611\u20135.","journal-title":"Synth Commun"},{"key":"849_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/S0960-894X(00)00193-1","volume":"10","author":"A Brancale","year":"2000","unstructured":"Brancale A, McGuigan C, Andrei G, Snoeck R, De Clercq E, Balzarini J. Bicyclic nucleoside inhibitors of varicella-zoster virus (VZV): the effect of a terminal halogen substitution in the side-chain. Bioorg Med Chem Lett. 2000;10:1215\u20137.","journal-title":"Bioorg Med Chem Lett"},{"key":"849_CR12","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1021\/jo001646c","volume":"66","author":"AN Cuzzupe","year":"2001","unstructured":"Cuzzupe AN, Hutton CA, Lilly MJ, Mann RK, McRae KJ, Zammit SC, et al. Total synthesis of the epidermal growth factor inhibitor (-)-reveromycin B. J Org Chem. 2001;66:2382\u201393.","journal-title":"J Org Chem."},{"key":"849_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0883-2889(91)90069-D","volume":"42","author":"BJ McBride","year":"1991","unstructured":"McBride BJ, Baldwin RM, Kerr JM, Wu J-L. A simple method for the preparation of 123I and 125I labeled iodobenzodiazepines. Int J Radiat Appl Instrum Part A Appl Radiat Isotopes. 1991;42:173\u20135.","journal-title":"Int J Radiat Appl Instrum Part A Appl Radiat Isotopes."},{"key":"849_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402\u20138.","journal-title":"Methods."},{"key":"849_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.866","volume":"11","author":"B Cai","year":"2023","unstructured":"Cai B, Chang S, Tian Y, Zhen S. CRISPR\/Cas9 for hepatitis B virus infection treatment. Immun Inflamm Dis. 2023;11: e866.","journal-title":"Immun Inflamm Dis."},{"key":"849_CR16","doi-asserted-by":"crossref","unstructured":"Yang YC, Yang HC. Recent progress and future prospective in HBV cure by CRISPR\/Cas. Viruses. 2021;14(1):4.","DOI":"10.3390\/v14010004"},{"key":"849_CR17","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1016\/j.ymthe.2022.05.013","volume":"30","author":"CL Gorsuch","year":"2022","unstructured":"Gorsuch CL, Nemec P, Yu M, Xu S, Han D, Smith J, et al. Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo. Mol Ther. 2022;30:2909\u201322.","journal-title":"Mol Ther."},{"key":"849_CR18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/176791a0","volume":"176","author":"DE Jones","year":"1955","unstructured":"Jones DE, Vernon CA. Nucleophilic substitution in vinylic halides. Nature. 1955;176:791\u20132.","journal-title":"Nature."},{"key":"849_CR19","unstructured":"Xie L. Inventor A novel iodine-containing antiviral agent. China patent ZL202011151673.9. 2020. https:\/\/www.qcc.com\/zhuanliDetail\/c0c32ae6ab39641ddca64010cb047cad.html."},{"key":"849_CR20","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1128\/AAC.41.7.1444","volume":"41","author":"SF Innaimo","year":"1997","unstructured":"Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997;41:1444\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"849_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","volume":"4","author":"A Ku","year":"2019","unstructured":"Ku A, Facca VJ, Cai Z, Reilly RM. Auger electrons for cancer therapy - a review. EJNMMI Radiopharm Chem. 2019;4:27.","journal-title":"EJNMMI Radiopharm Chem."},{"key":"849_CR22","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","volume":"75","author":"MG Martinez","year":"2021","unstructured":"Martinez MG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections. J Hepatol. 2021;75:706\u201317.","journal-title":"J Hepatol."},{"key":"849_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1196\/annals.1359.022","volume":"1058","author":"IV Panyutin","year":"2005","unstructured":"Panyutin IV, Sedelnikova OA, Bonner WM, Panyutin IG, Neumann RD. DNA damage produced by 125I-triplex-forming oligonucleotides as a measure of their successful delivery into cell nuclei. Ann N Y Acad Sci. 2005;1058:140\u201350.","journal-title":"Ann N Y Acad Sci."},{"key":"849_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ejps.2017.06.015","volume":"106","author":"Q Chen","year":"2017","unstructured":"Chen Q, Chen H, Wang W, Liu J, Liu W, Ni P, et al. Glycyrrhetic acid, but not glycyrrhizic acid, strengthened entecavir activity by promoting its subcellular distribution in the liver via efflux inhibition. Eur J Pharm Sci. 2017;106:313\u201327.","journal-title":"Eur J Pharm Sci."},{"key":"849_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100112","volume":"2","author":"CL Lai","year":"2020","unstructured":"Lai CL, Wong DK, Wong GT, Seto WK, Fung J, Yuen MF. Rebound of HBV DNA after cessation of nucleos\/tide analogues in chronic hepatitis B patients with undetectable covalently closed. JHEP Rep. 2020;2: 100112.","journal-title":"JHEP Rep."}],"container-title":["Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-024-00849-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13139-024-00849-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-024-00849-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T04:31:29Z","timestamp":1721190689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13139-024-00849-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1007\/s13139-024-00849-2","relation":{},"ISSN":["1869-3474","1869-3482"],"issn-type":[{"value":"1869-3474","type":"print"},{"value":"1869-3482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"18 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mu hua Cheng, Prof., and Liang jun Xie, M.D., declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Third Affiliated Hospital of Sun Yat-Sen University (No. 00377252).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The funders had no role in study design, data collection, analysis, and interpretation or preparation of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}